Dexamethasone-sparing on days 2–4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)

Hiroko Minatogawa, Takako Eguchi Nakajima, Kazuhiro Shimomura et al.|British Journal of Cancer|2023

Cited by 18